Shaping the Mitral Valve Market through Medicare

article image
ARTICLE SUMMARY:

Transcatheter mitral valve device developers jostle for advantage in providing feedback to CMS as it reconsiders its coverage policy.

Comments that came into the US Medicare agency last month broadly support an expanded and more flexible coverage policy for transcatheter mitral valve (TMV) treatments. But there are subtle distinctions between, on the one hand, first-to-market-mover Abbott Laboratories Inc.’s input to CMS and feedback from companies that are in earlier stages of development, underscoring how Medicare policies can play into competitive dynamics.

×



This article is restricted to subscribers only.

Sign in to continue reading.

Questions?

We're here to help! Please contact us at: